$INTI
Inhibitor Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224044473 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $493.6K
YoY Change -1.28%
% of Gross Profit
Research & Development $319.6K
YoY Change 22.57%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $813.2K
YoY Change 7.07%
Operating Profit -$813.2K
YoY Change 7.07%
Interest Expense $82.24K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$731.0K
YoY Change 10.75%
Income Tax
% Of Pretax Income
Net Earnings -$731.0K
YoY Change 9.96%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 172.3M shares 172.3M shares
Diluted Shares Outstanding 172.3M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.378M
YoY Change -33.14%
Cash & Equivalents $6.400M
Short-Term Investments
Other Short-Term Assets $73.14K
YoY Change 4.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.451M
YoY Change -32.85%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $6.451M
Total Long-Term Assets $0.00
Total Assets $6.451M
YoY Change -32.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.706K
YoY Change -98.17%
Accrued Expenses $42.85K
YoY Change -32.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.56K
YoY Change -71.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $3.000M
YoY Change 0.0%
Total Long-Term Liabilities $3.000M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.56K
Total Long-Term Liabilities $3.000M
Total Liabilities $3.045M
YoY Change -3.54%
SHAREHOLDERS EQUITY
Retained Earnings -$50.70M
YoY Change 6.48%
Common Stock $17.23K
YoY Change -99.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.407M
YoY Change
Total Liabilities & Shareholders Equity $6.451M
YoY Change -32.85%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$731.0K
YoY Change 9.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$720.4K
YoY Change 28.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -720.4K
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -720.4K
YoY Change 28.65%
FREE CASH FLOW
Cash From Operating Activities -$720.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenues
Revenues
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Revenues
Revenues
usd
CY2023Q3 us-gaap Revenues
Revenues
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
109243 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
6451442 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8949155 usd
CY2024Q3 us-gaap Assets
Assets
6451442 usd
CY2023Q4 us-gaap Assets
Assets
8949155 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1706 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
33731 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42853 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
631433 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
44559 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
665164 usd
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3044559 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3665164 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
17232 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
17202 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54087065 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54046845 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50697414 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48780056 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3406883 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5283991 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6451442 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8949155 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Revenues
Revenues
usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity File Number
EntityFileNumber
001-13467
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0793665
dei Entity Address Address Line1
EntityAddressAddressLine1
900 West Platt St Suite 200
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33606-2173
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
172323545 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6378304 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8839912 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73138 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
172323545 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
172023545 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
172023545 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319621 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
260765 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
794756 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
696156 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
493575 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1378404 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1435557 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
813196 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
759528 usd
us-gaap Operating Expenses
OperatingExpenses
2173160 usd
us-gaap Operating Expenses
OperatingExpenses
2131713 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-813196 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-759528 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2173160 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2131713 usd
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
82239 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
94768 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
255802 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
272836 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-730957 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-664760 usd
us-gaap Net Income Loss
NetIncomeLoss
-1917358 usd
us-gaap Net Income Loss
NetIncomeLoss
-1858877 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172323545 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172323545 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172012404 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172012404 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172242523 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172242523 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171925360 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
171925360 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5283991 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
21000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18090 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-684711 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4638370 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1160 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-501690 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4137840 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
864-2562
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
172323545 shares
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
498763 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-730957 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3406883 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
12250 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-654521 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7114475 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7114475 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1534 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-664760 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6451249 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6451249 usd
us-gaap Net Income Loss
NetIncomeLoss
-1917358 usd
us-gaap Net Income Loss
NetIncomeLoss
-1858877 usd
us-gaap Share Based Compensation
ShareBasedCompensation
40250 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13784 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-36105 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
46171 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-620605 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-111342 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2461608 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2002606 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
411000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-411000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2461608 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2413606 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8839912 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11951224 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6378304 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9537618 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_zh0MZIbTjWMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zHoRoKKWu5Kb">Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
290000 shares
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.07
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
20000.00 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2918 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares

Files In Submission

Name View Source Status
0001493152-24-044473-index-headers.html Edgar Link pending
0001493152-24-044473-index.html Edgar Link pending
0001493152-24-044473.txt Edgar Link pending
0001493152-24-044473-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
inti-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
inti-20240930_cal.xml Edgar Link unprocessable
inti-20240930_def.xml Edgar Link unprocessable
inti-20240930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
inti-20240930_pre.xml Edgar Link unprocessable